Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 43.35B 6.41B 5.59B 5.15B 4.85B 9.06B 604B 9.13B 61.37B 23.78B 298B 24.04B 23.53B 1,033B P/E 2026 *
31.8x
P/E 2027 * 26.3x
Enterprise Value 38.23B 5.65B 4.93B 4.54B 4.28B 7.98B 533B 8.05B 54.12B 20.97B 262B 21.2B 20.75B 911B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.08x
Free-Float
61.07%
Yield 2026 *
1.19%
Yield 2027 * 1.43%
Manager TitleAgeSince
Chief Executive Officer 70 07/10/1998
Chief Executive Officer 49 19/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 18/07/2011
Chairman 70 07/10/1998
Director/Board Member 65 18/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5.96B
-1.21%-3.33%+38.84%+145.38% 992B
-2.48%-4.23%+49.88%+39.07% 564B
-2.14%-3.76%+16.72%+56.15% 391B
-1.18%+0.68%+24.66%+16.53% 330B
-2.36%-2.30%+23.37%+11.59% 280B
-2.45%-0.84%+23.51%+30.06% 279B
-1.91%-1.06%-42.60%-49.25% 196B
-1.19%-0.04%+16.39%+47.00% 184B
-1.35%+1.88%+14.59%+56.94% 156B
Average -0.75%+0.41%+18.37%+39.27% 374.58B
Weighted average by Cap. -0.50%-0.49%+27.10%+63.21%

Financials

2026 *2027 *
Net sales 8.04B 1.19B 1.04B 956M 900M 1.68B 112B 1.69B 11.39B 4.41B 55.21B 4.46B 4.36B 192B 9.54B 1.41B 1.23B 1.13B 1.07B 1.99B 133B 2.01B 13.5B 5.23B 65.47B 5.29B 5.18B 227B
Net income 1.4B 208M 181M 167M 157M 293M 19.58B 296M 1.99B 770M 9.64B 779M 762M 33.47B 1.71B 253M 221M 203M 192M 358M 23.86B 360M 2.42B 939M 11.75B 949M 929M 40.79B
Net Debt -5.12B -757M -661M -609M -573M -1.07B -71.4B -1.08B -7.25B -2.81B -35.17B -2.84B -2.78B -122B -4.46B -659M -575M -530M -499M -932M -62.19B -940M -6.32B -2.45B -30.63B -2.47B -2.42B -106B
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!